Angiomax Patent Dispute: On-Sale Bar Applies To Distribution Agreement
Hospira's generic does not infringe The Medicine Company's patented method of making Angiomax, US Federal Circuit finds, but leaves question of whether TMC's distribution agreement covers manufacturing process for the district court to decide.
You may also be interested in...
Helsinn v. Teva challenges whether inventor's sale of an invention to a third party that must in turn keep the invention secret makes it unpatentable; America Invents Act amended "on-sale" bar provision.
Federal Circuit en banc court reverses panel decision, giving The Medicines Company chance to prove infringement and get Hospira's generic off the market.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.